Summary & Overview
HCPCS J9070: Cyclophosphamide, 100 mg
HCPCS Level II code J9070 identifies Cyclophosphamide, 100 mg, a widely used intravenous antineoplastic and immunosuppressive agent. Nationally, accurate coding of J9070 matters for chemotherapy billing, clinical documentation, and payer reimbursement for drug administration and acquisition costs. This code is relevant across hospital outpatient departments and infusion centers where parenteral chemotherapy is delivered.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9070 denotes, the typical sites of service, and the clinical context in which cyclophosphamide is administered. The publication outlines common billing considerations and common modifiers (listed separately), along with benchmarking and policy-related implications for national payers.
The article provides operational clarity for coding teams, revenue cycle staff, and clinical administrators on documenting and reporting J9070. It also summarizes where to expect this code on claims and what practical information billing personnel need to align coding with infusion services. Data not available in the input is noted where relevant.
Billing Code Overview
HCPCS Level II code J9070 represents Cyclophosphamide, 100 mg, an intravenous chemotherapy agent used in oncology and certain autoimmune conditions. The service type is medication administration for antineoplastic therapy, delivered as a drug supply line item.
The typical site of service for billing this code is an outpatient infusion center or hospital outpatient department where intravenous chemotherapy and other parenteral antineoplastic agents are administered. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old female with newly diagnosed diffuse large B-cell lymphoma presents to the outpatient oncology infusion center for systemic chemotherapy. The treatment plan includes an alkylating agent as part of a multi-agent regimen. Pharmacy dispenses J9070 (Cyclophosphamide, 100 mg) to prepare the ordered dose. The patient is checked in, vitals and lab results (CBC, renal and hepatic panel) are reviewed for adequacy, and premedication orders are administered per protocol. The oncology nurse verifies the regimen, confirms central venous access patency, and performs chemotherapy safety checks before infusion. Cyclophosphamide is administered intravenously over the prescribed infusion time in the outpatient infusion chair; nursing documents dose, lot number, route, start and stop times, and any immediate adverse reactions. Post-infusion instructions on hydration and hemorrhagic cystitis prevention (e.g., Mesna if ordered) are provided. Billing for the drug is submitted using HCPCS Level II code J9070 with applicable modifiers to reflect circumstances such as medical direction, unusual services, or site of care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Emergency service | When the cyclophosphamide infusion is provided during an emergency situation requiring immediate care. |